Shelling out $5B+, PerkinElmer pays the big bucks for antibody and reagent player

Max Gelman

Senior Editor

PerkinElmer has been busy on the acquisition front throughout the Covid-19 pandemic, and on Monday, the Massachusetts-based diagnostics and life sciences company added the biggest …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Shelling out $5B+, PerkinElmer pays the big bucks for antibody and reagent player

Max Gelman

Senior Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Judge halts some NIH cuts after 22 states sue

Merck KGaA confirms interest in acquiring cancer biotech SpringWorks

Decade after $8B deal, Roche offloads InterMune to mysterious specialty pharma

Eli Lilly inks $630M deal for Phase 1 MASH candidate

Boehringer Ingelheim touts success in second Phase 3 lung fibrosis trial

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

Shelling out $5B+, PerkinElmer pays the big bucks for an­ti­body and reagent play­er

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Shelling out $5B+, PerkinElmer pays the big bucks for antibody and reagent player